131 related articles for article (PubMed ID: 34975257)
1. Primary Breast Tumors with Mesenchymal Morphology.
Tevatia MS; Mishra P; Baranwal AK; Nichat PB; Shelly D; Awasthi S; Sengupta P
J Lab Physicians; 2021 Dec; 13(4):362-367. PubMed ID: 34975257
[No Abstract] [Full Text] [Related]
2. Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.
Akrida I; Nikou S; Gyftopoulos K; Argentou M; Kounelis S; Zolota V; Bravou V; Papadaki H
Histol Histopathol; 2018 Sep; 33(9):937-949. PubMed ID: 29608014
[TBL] [Abstract][Full Text] [Related]
3. Expression of lymphoid enhancer-binding factor 1 in breast fibroepithelial lesions.
Chen PH; Bossuyt V; Reisenbichler E
Hum Pathol; 2021 Feb; 108():68-75. PubMed ID: 33245988
[TBL] [Abstract][Full Text] [Related]
4. Epithelial to mesenchymal transition (EMT) in metaplastic breast cancer and phyllodes breast tumors.
Akrida I; Mulita F; Plachouri KM; Benetatos N; Maroulis I; Papadaki H
Med Oncol; 2023 Dec; 41(1):20. PubMed ID: 38104042
[TBL] [Abstract][Full Text] [Related]
5. Fibroepithelial lesions; The WHO spectrum.
Krings G; Bean GR; Chen YY
Semin Diagn Pathol; 2017 Sep; 34(5):438-452. PubMed ID: 28688536
[TBL] [Abstract][Full Text] [Related]
6. β-Catenin mutations in 2 nested stromal epithelial tumors of the liver--a neoplasia with defective mesenchymal-epithelial transition.
Assmann G; Kappler R; Zeindl-Eberhart E; Schmid I; Häberle B; Graeb C; Jung A; Müller-Höcker J
Hum Pathol; 2012 Nov; 43(11):1815-27. PubMed ID: 22749188
[TBL] [Abstract][Full Text] [Related]
7. The Epithelial-Mesenchymal Transition, E-cadherin and Tumor Progression in Ovarian Serous Tumors.
Bozhkova DM; Poryazova-Markova EG
Folia Med (Plovdiv); 2019 Jun; 61(2):296-302. PubMed ID: 31301662
[TBL] [Abstract][Full Text] [Related]
8. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
9. Expression of EMT markers and mode of surgery are prognostic in phyllodes tumors of the breast.
Feng X; Zhao L; Shen H; Liu X; Yang Y; Lv S; Niu Y
Oncotarget; 2017 May; 8(20):33365-33374. PubMed ID: 28380418
[TBL] [Abstract][Full Text] [Related]
10. Immunoexpression of Epithelial Mesenchymal Transition Proteins E-Cadherin, β-Catenin, and N-Cadherin in Oral Squamous Cell Carcinoma.
Angadi PV; Patil PV; Angadi V; Mane D; Shekar S; Hallikerimath S; Kale AD; Kardesai SG
Int J Surg Pathol; 2016 Dec; 24(8):696-703. PubMed ID: 27312520
[TBL] [Abstract][Full Text] [Related]
11. Analysis of metaplastic breast carcinoma: FNAC; histopathology and immunohistochemistry are complementary for diagnosis.
Abd El Hafez A; Shawky Ael-A
Breast Dis; 2013 Jan; 34(2):67-75. PubMed ID: 24077354
[TBL] [Abstract][Full Text] [Related]
12. Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma.
González-Martínez S; Pérez-Mies B; Pizarro D; Caniego-Casas T; Cortés J; Palacios J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299016
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
[TBL] [Abstract][Full Text] [Related]
14. Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.
Franceschi T; Durieux E; Morel AP; de Saint Hilaire P; Ray-Coquard I; Puisieux A; Devouassoux-Shisheboran M
Virchows Arch; 2019 Jul; 475(1):85-94. PubMed ID: 30739164
[TBL] [Abstract][Full Text] [Related]
15. Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer.
Hollestelle A; Peeters JK; Smid M; Timmermans M; Verhoog LC; Westenend PJ; Heine AA; Chan A; Sieuwerts AM; Wiemer EA; Klijn JG; van der Spek PJ; Foekens JA; Schutte M; den Bakker MA; Martens JW
Breast Cancer Res Treat; 2013 Feb; 138(1):47-57. PubMed ID: 23338761
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-to-mesenchymal transition in metaplastic breast carcinomas with chondroid differentiation: expression of the E-cadherin repressor Snail.
Gwin K; Buell-Gutbrod R; Tretiakova M; Montag A
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):526-31. PubMed ID: 20697265
[TBL] [Abstract][Full Text] [Related]
17. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast.
Vidal M; Peg V; Galván P; Tres A; Cortés J; Ramón y Cajal S; Rubio IT; Prat A
Mol Oncol; 2015 Jun; 9(6):1081-90. PubMed ID: 25687451
[TBL] [Abstract][Full Text] [Related]
18. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
[TBL] [Abstract][Full Text] [Related]
19. Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis.
Papathomas TG; Duregon E; Korpershoek E; Restuccia DF; van Marion R; Cappellesso R; Sturm N; Rossi G; Coli A; Zucchini N; Stoop H; Oosterhuis W; Ventura L; Volante M; Fassina A; Dinjens WN; Papotti M; de Krijger RR
Hum Pathol; 2016 Dec; 58():113-122. PubMed ID: 27589897
[TBL] [Abstract][Full Text] [Related]
20. Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression.
Jørgensen CLT; Forsare C; Bendahl PO; Falck AK; Fernö M; Lövgren K; Aaltonen K; Rydén L
Breast Cancer Res Treat; 2020 Jun; 181(2):369-381. PubMed ID: 32300922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
